A Randomized, Controlled Study on the Efficacy and Safety of Octreotide Acetate in Microspheres in the Therapy of Patients With Moderately Severe or Severe Non-Proliferate Diabetic Retinopathy (NPDR) or Low Risk Proliferative Diabetic Retinopathy (PDR).
Latest Information Update: 10 May 2012
At a glance
- Drugs Octreotide (Primary)
- Indications Diabetic retinopathy
- Focus Therapeutic Use
- 30 Apr 2012 Extension study terminated because of inconsistent treatment benefit.
- 30 Apr 2012 Extension study terminated because of inconsistent treatment benefit.
- 16 Nov 2011 Actual end date (Dec 2005) added as reported by ClinicalTrials.gov.